Testing a cholesterol medication to reduce lingering inflammation after tuberculosis treatment

This trial is testing whether atorvastatin, a medication commonly used to lower cholesterol, can help reduce stubborn inflammation that often remains in the lungs even after tuberculosis treatment successfully cures the infection. Researchers have found that even after patients are declared cured, their lungs can still show signs of inflammation and possibly remaining bacteria. The hope is that this medication might help clear these lingering problems.

Standard tuberculosis treatment doesn't always completely eliminate the bacteria or the inflammation it causes in the lungs. Many patients finish their treatment but still have signs of lung damage or ongoing infection. This trial wants to see if the medication can help finish the job that standard treatment started, reducing the risk of tuberculosis coming back.